marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
DiaMedica Therapeutics Financial Ratios 2011-2024 | DMAC
Annual Financial Ratios DiaMedica Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.7 | -3.1 | -4.0 | -10.9 | -4.7 | -5.2 | -6.4 | -5.4 | -5.5 | -0.6 | -6.0 | -4.8 | - |
P/S |
- | - | - | - | - | 59.3 | - | - | - | - | - | - | - |
EPS |
-0.6 | -0.5 | -0.7 | -0.8 | -0.9 | -0.7 | -0.7 | - | - | - | - | - | - |
EV (Enterprise Value) |
87.3 M | 37.3 M | 49.1 M | 129 M | 47.4 M | 14.1 M | 28.3 M | 12.7 M | 9.37 M | 4.79 M | 45.9 M | 50.1 M | 365 K |
EBITDA per Share |
-0.65 | -0.53 | -0.66 | -0.747 | -0.894 | -0.714 | -0.721 | -0.477 | -0.382 | -1.59 | -2.31 | -3.15 | - |
EV/EBITDA |
-2.7 | -10.2 | -4.3 | -2.3 | -6.1 | -4.6 | -5.6 | -0.6 | -6.6 | -6.0 | - | ||
PEG |
1982.97 | 0.65 | -0.42 | 0.72 | 0.23 | 1.86 | 0.08 | -0.72 | -0.08 | -0.02 | -0.17 | 0.13 | - |
P/B |
1.7 | 1.2 | 1.2 | 5.2 | 6.5 | 1.7 | 34.2 | 9.7 | -6.4 | -1.9 | 32.1 | 21.4 | - |
P/CF |
-4.9 | -3.7 | -4.4 | -14.5 | -5.5 | -5.2 | -7.0 | -4.0 | -5.8 | -0.8 | -7.9 | -8.7 | - |
ROE % |
-37.96 | -42.97 | -30.87 | -47.25 | -139.81 | -33.68 | -533.17 | -178.42 | 117.33 | 315.11 | -536.39 | -443.83 | - |
ROA % |
-35.78 | -39.76 | -29.84 | -43.75 | -117.63 | -31.27 | -236.40 | -118.70 | -648.61 | -1710.92 | -255.01 | -261.27 | - |
ROCE % |
-41.40 | -43.44 | -30.99 | -47.93 | -138.81 | -32.55 | -535.04 | -199.16 | 155.64 | 316.17 | -537.57 | -446.22 | - |
Current Ratio |
- | - | - | 13.8 | 6.7 | 13.9 | 1.5 | 3.0 | 0.2 | 0.1 | 1.7 | 1.6 | - |
DSO |
- | - | - | - | - | 569.4 | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios DiaMedica Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.15 | -0.13 | -0.14 | - | -0.12 | -0.16 | -0.2 | - | -0.12 | -0.13 | -0.13 | - | -0.18 | -0.17 | -0.19 | - | -0.19 | -0.17 | -0.19 | - | -0.2 | -0.21 | -0.27 | - | -0.18 | -0.22 | -0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | -0.15 | - | - | - | -0.21 | - | -0.12 | -0.13 | -0.13 | - | -0.18 | -0.18 | -0.19 | - | -0.2 | -0.19 | -0.18 | - | -0.22 | -0.23 | -0.29 | - | -0.19 | -0.24 | -0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-41.81 | -36.77 | -34.68 | -35.04 | -43.76 | -44.44 | -45.85 | -26.23 | -33.56 | -32.18 | -39.39 | -39.10 | -51.37 | -56.31 | -49.71 | -31.11 | -63.24 | -83.11 | -106.01 | -107.25 | -115.39 | -91.40 | -69.18 | -22.16 | -22.16 | -14.01 | -3.82 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-39.11 | -34.85 | -33.05 | -32.35 | -40.61 | -41.18 | -42.52 | -25.12 | -32.21 | -31.04 | -37.53 | -37.00 | -48.36 | -52.64 | -46.41 | -28.80 | -55.84 | -71.52 | -89.99 | -90.24 | -97.80 | -78.32 | -60.51 | -20.57 | -20.57 | -13.01 | -3.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-46.29 | -41.23 | -38.62 | -37.25 | -46.06 | -45.66 | -46.69 | -26.40 | -33.66 | -32.11 | -39.74 | -39.42 | -52.16 | -57.63 | -51.47 | -32.34 | -66.75 | -88.42 | -113.46 | -114.07 | -122.79 | -97.11 | -72.53 | -27.24 | -27.24 | -18.52 | -7.66 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency